Quarterly report pursuant to Section 13 or 15(d)

Stockholders Equity (Common Stock and Equity Offerings) (Narrative) (Details)

v3.23.1
Stockholders Equity (Common Stock and Equity Offerings) (Narrative) (Details) - USD ($)
 3 Months Ended
Jan. 01, 2022
Jul. 22, 2016
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
May 24, 2021
Dec. 04, 2020
Aug. 31, 2018
Stockholders' Equity                
Common stock, shares authorized     200,000,000   200,000,000      
Common stock par value (in dollars per share)     $ 0.0001   $ 0.0001      
Preferred stock, shares authorized     2,000,000   2,000,000      
Preferred stock, shares issued     250,000   250,000      
Aggregate value of shares subscribed     $ 0   $ 1,109,000      
Common stock, shares issued     7,293,242   7,100,111      
Common stock, shares issuable     0   187,134      
Fortress Biotech, Inc [Member]                
Stockholders' Equity                
Percentage of fully diluted equity 2.50% 2.50%            
Expenses from related party transaction     $ 100,000 $ 300,000        
Issuance of common shares (in shares)       6,292        
Shares issued, price per share       $ 25.95        
At the Market Offering [Member]                
Stockholders' Equity                
Agent commission (as a percent)               3.00%
Issuance of common shares (in shares)       185,000        
Shares issued, price per share       $ 15.00        
Proceeds from issuance of common shares       $ 2,800,000        
Aggregate fees of stock issuance       49,000        
Registration Statements [Member]                
Stockholders' Equity                
Sale of Stock aggregate offering price - Founders Agreement           $ 200,000,000.0 $ 100,000,000.0  
Shares available for future issuance - Founders Agreement     $ 8,000,000.0          
General and administrative [Member] | Fortress Biotech, Inc [Member]                
Stockholders' Equity                
Expenses from related party transaction       $ 800,000